# PDUFA dates June 2026: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2026-06

> 164 FDA catalysts are dated in June 2026, including 13 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in June 2026?

PDUFA dates in June 2026: VEPPANU (vepdegestrant, ARVN) on June 5, 2026; IBRANCE® (palbociclib, ARVN) on June 5, 2026; GSK plc (GSK) on June 18, 2026; tebipenem (SPRO) on June 18, 2026; carbapenem (SPRO) on June 18, 2026; Kiniksa Pharmaceuticals International, plc (KNSA) on June 19, 2026; and 7 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2026-06)

Source: Press release filed with the SEC (EX-99), accession 0001655759-25-000147, https://www.sec.gov/Archives/edgar/data/1655759/000165575925000147/arvnstrategicupdaterelea.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/fda-calendar/2026-06#answer

## PDUFA dates in June 2026

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| June 5, 2026 | ARVINAS, INC. | ARVN | VEPPANU (vepdegestrant) | with estrogen receptor-positive | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000147/arvnstrategicupdaterelea.htm) |
| June 5, 2026 | ARVINAS, INC. | ARVN | IBRANCE® (palbociclib) |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/arvn-20251231.htm) |
| June 18, 2026 | GSK plc | GSK |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426000892/a5979rv2.htm) |
| June 18, 2026 | Spero Therapeutics, Inc. | SPRO | tebipenem |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/d147628dex991.htm) |
| June 18, 2026 | Spero Therapeutics, Inc. | SPRO | carbapenem |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1701108/000119312526277506/d51395d8k.htm) |
| June 19, 2026 | Kiniksa Pharmaceuticals International, plc | KNSA |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1730430/000110465926050359/knsa-20260331x10q.htm) |
| June 19, 2026 | Merck & Co., Inc. | MRK | WELIREG® (belzutifan) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm) |
| June 26, 2026 | Viridian Therapeutics, Inc.\DE | VRDN | Lumvoa™ (veligrotug) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744dex991.htm) |
| June 29, 2026 | Arcutis Biotherapeutics, Inc. | ARQT | ZORYVE (roflumilast) | plaque psoriasis in children down | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000017/pressreleaseex991q42025.htm) |
| June 29, 2026 | Unicycive Therapeutics, Inc. | UNCY | oxylanthanum |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/ea029027701ex99-1.htm) |
| June 30, 2026 | Viridian Therapeutics, Inc.\DE | VRDN | Lumvoa™ (veligrotug) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/d149508dex991.htm) |
| June 30, 2026 | IONIS PHARMACEUTICALS INC | IONS | TRYNGOLZA (olezarsen) | severe hypertriglyceridemia, or sHTG, with an action date of June 30, 2026 | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/ef20071749_ex99-1.htm) |
| June 30, 2026 | Viridian Therapeutics, Inc.\DE | VRDN |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977dex992.htm) |

## All catalysts in June 2026

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 1, 2026 | [KAMADA LTD FDA approval](https://sec-api.dev/companies/kmda/catalysts) | KMDA |  | completed, approved | "1, 2026 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company's new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567529/000121390026063140/ea029288601ex99-1.htm)) |
| June 1, 2026 | [Indegene complete response letter (CRL)](https://sec-api.dev/pdufa/indegene) | CING |  | completed, complete response letter | "June 1, 2026, the FDA issued a Complete Response Letter (CRL) for the CTx-1301 (dexmethylphenidate HCl) NDA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm)) |
| June 1, 2026 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX |  | completed, positive | "Paris: FR0012333284 - ABVX / Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced positive topline results from the Phase 3 ABTECT maintenance trial evaluating obefazimod, its investigational oral, first-in-class miR-124 enhancer, in adults with moderately to severely active ulcerative colitis ("UC")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526252360/d98688dex991.htm)) |
| June 1, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer | completed | "NCT03682068 (Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-01 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03682068)) |
| June 2026 | [OT-101 primary completion](https://sec-api.dev/pdufa/ot-101) | OTLC | Pancreatic Ductal Adenocarcinoma | delayed | "NCT06079346 (A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-06-01 (ESTIMATED); Lead Sponsor Oncotelic Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079346)) |
| June 1, 2026 | [REDEMPLO (plozasiran) primary completion](https://sec-api.dev/pdufa/plozasiran) | ARWR | Hypertriglyceridemia | completed | "NCT06347133 (Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-01 (ACTUAL); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06347133)) |
| June 1, 2026 | [Efinopegdutide topline data readout](https://sec-api.dev/pdufa/efinopegdutide) | MRK |  | completed | "NCT06482112 (Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06482112?tab=results)) |
| June 2026 | [ARCT-810 primary completion](https://sec-api.dev/pdufa/arct-810) | ARCT | OTC Deficiency; Ornithine Transcarbamylase Deficiency; OTCD | delayed | "NCT06488313 (A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-06-01 (ESTIMATED); Lead Sponsor Arcturus Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06488313)) |
| June 1, 2026 | [New toothpaste containing snf primary completion](https://sec-api.dev/pdufa/new-toothpaste-containing-snf) | CL | Enamel Erosion | completed | "NCT07442136 (Clinical Study to Assess the Efficacy of New Toothpaste Containing SnF as Compared to Colgate Cavity Protection Toothpaste on the Reduction of Enamel Erosion): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-01 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07442136)) |
| June 2, 2026 | [PTR (ptr) complete response letter (CRL)](https://sec-api.dev/pdufa/ptr) | CING | Attention Deficit/Hyperactivity Disorder | completed, complete response letter | "CITY, Kan., June 2, 2026 — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter for its New Drug Application ("NDA") for CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/ex99-1.htm)) |
| June 2, 2026 | [Cingulate Inc. complete response letter (CRL)](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed, complete response letter | "June 2, 2026, the Company announced that the FDA has issued a CRL for its New Drug Application for CTx-1301." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/form8-k.htm)) |
| June 2, 2026 | [Lanifibranor FDA approval](https://sec-api.dev/pdufa/lanifibranor) | IVA |  | completed, approved | "On June 2, 2026, we entered into a subscription agreement with funds and accounts managed by BlackRock and Claret Capital Partners (the "Lenders") providing for the issuance of new senior secured debt instruments for an aggregate committed principal amount of up to €130.0 million, plus an additional uncommitted tranche of up to €20.0 million subject to mutual consent following FDA approval of the NDA for lanifibranor (the "Subscription Agreement") (together, the "Debt Financing Transaction")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630xex99d1.htm)) |
| June 2, 2026 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Locally Advanced or Metastatic Unresectable Urothelial Cancer | completed | "NCT04527991 (Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-04 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-06-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04527991?tab=results)) |
| June 2, 2026 | [TAK-341 topline data readout](https://sec-api.dev/pdufa/tak-341) | TAK | Multiple System Atrophy | completed | "NCT05526391 (A Study of TAK-341 in Treatment of Multiple System Atrophy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05526391?tab=results)) |
| June 2, 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Overweight | completed | "NCT06075667 (A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-02 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06075667)) |
| June 2, 2026 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | completed | "NCT06534411 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-02 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06534411)) |
| June 3, 2026 | [Avalyn Pharma Inc. earnings report](https://sec-api.dev/companies/avln/catalysts) | AVLN |  | completed | "Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1540171/000119312526254581/ck0001540171-ex99_1.htm)) |
| June 4, 2026 | [Joenja® (leniolisib) NDA/BLA acceptance](https://sec-api.dev/pdufa/leniolisib) | PHAR | children aged 4 to 11 years with APDS | completed | "On June 4, 2026, we announced that the U.S. Food and Drug Administration (FDA) had accepted our resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja as a treatment for children aged 4 to 11 years with APDS." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000033/a2026hy1pressrelease.htm)) |
| June 4, 2026 | [Ml-007c-ma bid primary completion](https://sec-api.dev/pdufa/ml-007c-ma-bid) | MPLT | Schizophrenia | completed | "NCT07038876 (A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-04 (ACTUAL); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07038876)) |
| June 4, 2026 | [Pociredir primary completion](https://sec-api.dev/pdufa/pociredir) | FULC | Sickle Cell Disease | withdrawn | "NCT07401823 (Open-Label Extension Study to Pioneer Study 6058-SCD-101): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-04 (ACTUAL); Lead Sponsor Fulcrum Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07401823)) |
| June 5, 2026 | [VEPPANU (vepdegestrant) NDA/BLA acceptance](https://sec-api.dev/pdufa/vepdegestrant) | ARVN |  | completed | "In the third quarter of 2025, we announced that the FDA accepted the NDA for vepdegestrant and assigned a PDUFA action date of June 5, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1655759/000162828026069464/arvn-20260930.htm)) |
| June 5, 2026 | [VEPPANU (vepdegestrant) PDUFA date](https://sec-api.dev/pdufa/vepdegestrant) | ARVN | with estrogen receptor-positive | completed, approved | "Vepdegestrant was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) action date of June 5, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000147/arvnstrategicupdaterelea.htm)) |
| June 5, 2026 | [IBRANCE® (palbociclib) PDUFA date](https://sec-api.dev/pdufa/palbociclib) | ARVN |  | completed, approved | "•Footnotes included in the graphic above: (a) Includes relapsed/refractory angioimmunoblastic T-cell lymphoma, or AITL, and relapsed/refractory mature B cell NHL; (b) PDUFA date of June 5, 2026; and (c) Phase 1/2 combination clinical trials with palbociclib, atirmociclib, abemaciclib, ribociclib, samuraciclib, everolimus." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/arvn-20251231.htm)) |
| June 5, 2026 | [Hympavzi (marstacimab-hncq) label expansion decision](https://sec-api.dev/pdufa/marstacimab-hncq) | PFE |  | completed, approved | "BLA761369 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20260605, review_priority PRIORITY; sponsor_name PFIZER INC; product HYMPAVZI (MARSTACIMAB-HNCQ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761369%22)) |
| June 5, 2026 | [Ultomiris® (ravulizumab) topline data readout](https://sec-api.dev/pdufa/ravulizumab) | AZN | Paroxysmal Nocturnal Hemoglobinuria; PNH | completed | "NCT06578949 (Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-06-05." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06578949?tab=results)) |
| June 5, 2026 | [MK-1167 primary completion](https://sec-api.dev/pdufa/mk-1167) | MRK | Alzheimer Disease; Dementia | withdrawn | "NCT06721156 (A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06721156)) |
| June 6, 2026 | [Cullinan Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | scheduled | "The initial data will be presented in a poster session at the EULAR 2026 Congress on June 6, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm)) |
| June 6, 2026 | [Colgate 360 supraclean manual toothbrush brush with 0.76% na mfp, (1000 ppm f) primary completion](https://sec-api.dev/pdufa/colgate-360-supraclean-manual-toothbrush-brush-with-0-76-na-mfp-1000-ppm-f) | CL | Bacterial Load Reduction | completed | "NCT07471477 (Bacterial Reduction for a Manual Toothbrush With a 360-Degree Mouth Cleaner Design Versus a Standard Toothbrush): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-06 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07471477)) |
| June 8, 2026 | [Vopimetostat interim data readout](https://sec-api.dev/pdufa/vopimetostat) | TNGX |  | completed, positive | "BOSTON, June 8, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced positive initial data from its ongoing Phase 1/2 study of vopimetostat, an investigational PRMT5 inhibitor with first- and best-in-class potential, in combination with Revolution Medicines' RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312526260679/d158334dex991.htm)) |
| June 8, 2026 | [Seaport Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sptx/catalysts) | SPTX |  | completed | "Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2042347/000119312526260671/sptx-ex99_1.htm)) |
| June 8, 2026 | [Entyvio® (vedolizumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/vedolizumab) | TAK | moderately to severely active ulcerative colitis | completed | "On 8 June 2026, the Company announced that the FDA had accepted for review a BLA for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326003974/exh_993.htm)) |
| June 8, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Non-Small Cell Lung Cancer | completed | "NCT03516981 (A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-13 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03516981?tab=results)) |
| June 8, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Solid Tumors | completed | "NCT04123366 (Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-08 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04123366)) |
| June 8, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Colorectal Cancer | completed | "NCT04895722 (Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895722?tab=results)) |
| June 8, 2026 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | SNY | Lichen Simplex Chronicus | completed | "NCT06687967 (A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-08 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06687967)) |
| June 8, 2026 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | SNY | Lichen Simplex Chronicus | completed | "NCT06687980 (A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-08 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06687980)) |
| June 9, 2026 | [Ebglyss (lebrikizumab-lbkz) label expansion decision](https://sec-api.dev/pdufa/lebrikizumab-lbkz) | LLY |  | completed, approved | "BLA761306 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260609, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product EBGLYSS (LEBRIKIZUMAB-LBKZ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761306%22)) |
| June 9, 2026 | [Ziltivekimab b primary completion](https://sec-api.dev/pdufa/ziltivekimab-b) | NVO | Cardiovascular Risk; Chronic Kidney Disease; Inflammation | completed | "NCT05021835 (ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-09 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05021835)) |
| June 9, 2026 | [ENHERTU (trastuzumab deruxtecan) primary completion](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | "NCT05048797 (A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-09 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05048797)) |
| June 2026 | [INE963 primary completion](https://sec-api.dev/pdufa/ine963) | NVS | Uncomplicated Plasmodium Falciparum Malaria | delayed | "NCT05750628 (Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-06-09 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05750628)) |
| June 10, 2026 | [Humacyte, Inc. topline data readout](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed, positive | "On June 10, 2026, we announced positive top-line interim results for our V012 Phase 3 clinical trial of the ATEVs in female patients with end-stage kidney disease ("ESKD") requiring hemodialysis access." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1818382/000110465926072961/tm2616944-3_424b5.htm)) |
| June 10, 2026 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | withdrawn | "NCT05660967 (Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-10 (ACTUAL); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05660967)) |
| June 10, 2026 | [Riliprubart primary completion](https://sec-api.dev/pdufa/riliprubart) | SNY |  | completed | "NCT06290128 (A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06290128)) |
| June 10, 2026 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06407934 (A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06407934)) |
| June 11, 2026 | [Rafael Holdings, Inc. earnings report](https://sec-api.dev/companies/rfl/catalysts) | RFL |  | completed | "Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm)) |
| June 12, 2026 | [WELIREG® (belzutifan) label expansion decision](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "NDA215383 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22)) |
| June 12, 2026 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| June 12, 2026 | [Truqap (capivasertib) label expansion decision](https://sec-api.dev/pdufa/capivasertib) | AZN |  | completed, approved | "NDA218197 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority STANDARD; sponsor_name ASTRAZENECA; product TRUQAP (CAPIVASERTIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218197%22)) |
| June 12, 2026 | [REDEMPLO (plozasiran) primary completion](https://sec-api.dev/pdufa/plozasiran) | ARWR | Severe Hypertriglyceridemia | completed | "NCT06347003 (Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-12 (ACTUAL); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06347003)) |
| June 12, 2026 | [Fasedienol nasal spray - fasedienol nasal spray primary completion](https://sec-api.dev/pdufa/fasedienol-nasal-spray-fasedienol-nasal-spray) | VTGN | Social Anxiety Disorder | completed | "NCT06809179 (A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-12 (ACTUAL); Lead Sponsor VistaGen Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06809179)) |
| June 2026 | [Adrenalin 0.5mg injectable product primary completion](https://sec-api.dev/pdufa/adrenalin) | NSRX | Anaphylaxis Food | delayed | "NCT07045701 (FMXIN002 in Patients at Risk of Anaphylaxis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2026-06-12 (ESTIMATED); Lead Sponsor Nasus Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07045701)) |
| June 12, 2026 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-192 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| June 12, 2026 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 SUPPL-44 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| June 13, 2026 | [EnGene Therapeutics Inc. earnings report](https://sec-api.dev/companies/engn/catalysts) | ENGN |  | completed | "Exhibit 99.1 enGene Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/engn-ex99_1.htm)) |
| June 15, 2026 | [Vistagen Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vtgn/catalysts) | VTGN |  | completed | "Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1411685/000162828026043232/vtgn-20260615xex991.htm)) |
| June 15, 2026 | [Ozekibart NDA/BLA acceptance](https://sec-api.dev/pdufa/ozekibart) | INBX | with unresectable or metastatic conventional chondrosarcoma | completed | "On June 15, 2026, the Company announced that the FDA has accepted for filing its BLA seeking approval of ozekibart for the treatment of patients with unresectable or metastatic conventional chondrosarcoma." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/inhibrx-20260615.htm)) |
| June 15, 2026 | [SPY002 topline data readout](https://sec-api.dev/pdufa/spy002) | SYRE |  | completed, positive | "On June 15, 2026, the Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 for the treatment of moderately-to-severely active UC." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000083/syre-20260615.htm)) |
| June 15, 2026 | [Entyvio® (vedolizumab) topline data readout](https://sec-api.dev/pdufa/vedolizumab) | TAK | Ulcerative Colitis; Crohn's Disease | completed | "NCT04738942 (A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04738942?tab=results)) |
| June 15, 2026 | [Pembrolizumab/vibostolimab primary completion](https://sec-api.dev/pdufa/pembrolizumab-vibostolimab) | MRK | Carcinoma, Non-Small-Cell Lung | completed | "NCT05298423 (Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-15 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05298423)) |
| June 2026 | [Oral hexavalent reassortant rotavirus attenuated live vaccine primary completion](https://sec-api.dev/pdufa/oral-hexavalent-reassortant-rotavirus-attenuated-live-vaccine) | SVA | Rotavirus Gastroenteritis | delayed | "NCT06967272 (PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-06-15 (ESTIMATED); Lead Sponsor Sinovac Life Sciences Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06967272)) |
| June 16, 2026 | [VS-7375 trial start](https://sec-api.dev/pdufa/vs-7375) | VSTM |  | completed | "On June 16, 2026, the Company also announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926074915/tm2618108d1_8k.htm)) |
| June 16, 2026 | [CNM-Au8 (cnm-au8) NDA/BLA acceptance](https://sec-api.dev/pdufa/cnm-au8) | CLNN |  | completed | "The Tranche A Warrants were exercisable immediately and will expire on the earlier of (i) sixty (60) days following the date of our public announcement that the filing of a New Drug Application ("NDA") for CNM-Au8 has been accepted by the U.S. Food and Drug Administration ("FDA"), or (ii) June 16, 2026." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926030521/clnn20260911_424b5.htm)) |
| June 16, 2026 | [Biologics interim data readout](https://sec-api.dev/pdufa/biologics) | HCWB |  | completed, positive | "Fla., June 16, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today announced a positive preliminary human data readout for the first two dose cohorts from its dose-escalating Phase 1 clinical trial of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828673/000149315226028807/ex99-1.htm)) |
| June 16, 2026 | [Qulipta (atogepant) topline data readout](https://sec-api.dev/pdufa/atogepant) | ABBV | Chronic Migraine | completed | "NCT05216263 (Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-02 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05216263?tab=results)) |
| June 16, 2026 | [XL092 primary completion](https://sec-api.dev/pdufa/xl092) | EXEL | Colorectal Cancer | completed | "NCT05425940 (Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-16 (ACTUAL); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05425940)) |
| June 16, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Type 2 Diabetes; Obesity; Overweight | completed | "NCT05929079 (A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-16 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05929079)) |
| June 16, 2026 | [Trevogrumab-part a primary completion](https://sec-api.dev/pdufa/trevogrumab-part-a) | REGN | Obesity | completed | "NCT06299098 (A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-16 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06299098)) |
| June 17, 2026 | [Odyssey Therapeutics, Inc. earnings report](https://sec-api.dev/companies/odtx/catalysts) | ODTX |  | completed | "Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1882782/000119312526274291/odtx-ex99_1.htm)) |
| June 17, 2026 | [Corcept NDA/BLA submission](https://sec-api.dev/pdufa/corcept) | CORT | Cushing's syndrome | completed | "On June 17, 2026, Corcept Therapeutics Incorporated (the "Company") issued a press release announcing that the Company has resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing's syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/d159941d8k.htm)) |
| June 17, 2026 | [Tebipenem FDA approval](https://sec-api.dev/pdufa/tebipenem) | SPRO | complicated urinary tract infections | completed, approved | "On June 17, 2026, the Company and GSK announced that the FDA approved GSK's NDA resubmission for Utebzi (tebipenem pivoxil)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm)) |
| June 17, 2026 | [Lifyorli™ (relacorilant) NDA/BLA submission](https://sec-api.dev/pdufa/relacorilant) | CORT |  | completed | "Based on the positive outcome of the requested analyses, we resubmitted our NDA to the FDA on June 17, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1088856/000162828026069501/cort-20260930.htm)) |
| June 17, 2026 | [Ordspono™ (odronextamab) primary completion](https://sec-api.dev/pdufa/odronextamab) | REGN | B-cell Non-Hodgkin Lymphoma (B-NHL) | completed | "NCT03888105 (A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-17 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03888105)) |
| June 17, 2026 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | BMY | Extensive-stage Small Cell Lung Cancer | completed | "NCT04702880 (A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-22 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-06-17." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04702880?tab=results)) |
| June 17, 2026 | [ION363 primary completion](https://sec-api.dev/pdufa/ion363) | IONS | Amyotrophic Lateral Sclerosis | completed | "NCT04768972 (FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-17 (ACTUAL); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04768972)) |
| June 17, 2026 | [GSK3036656 topline data readout](https://sec-api.dev/pdufa/gsk3036656) | GSK | Tuberculosis | completed | "NCT05382312 (Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-27 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-17." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05382312?tab=results)) |
| June 17, 2026 | [REDEMPLO (plozasiran) primary completion](https://sec-api.dev/pdufa/plozasiran) | ARWR | Severe Hypertriglyceridemia | completed | "NCT06347016 (Study of Plozasiran in Adults With Severe Hypertriglyceridemia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-17 (ACTUAL); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06347016)) |
| June 17, 2026 | [INE963 primary completion](https://sec-api.dev/pdufa/ine963) | NVS | Uncomplicated Plasmodium Falciparum Malaria | completed | "NCT07811882 (Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811882)) |
| June 17, 2026 | [Utebzi (tebipenem pivoxil hydrobromide) FDA approval](https://sec-api.dev/pdufa/tebipenem-pivoxil) | GSK |  | completed, approved | "Utebzi \| tebipenem pivoxil \| 6/17/2026 \| To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| June 18, 2026 | [Earth Science Tech, Inc. earnings report](https://sec-api.dev/companies/etst/catalysts) | ETST |  | completed | "Science Tech, Inc. Reports Fiscal Year-End Financial Results for March 31, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1538495/000149315226029200/ex99-1.htm)) |
| June 18, 2026 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/ef20076145_ex99-1.htm)) |
| June 18, 2026 | [GSK plc PDUFA date](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | scheduled | "The PDUFA date has been set as 18 June 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426000892/a5979rv2.htm)) |
| June 18, 2026 | [Tebipenem PDUFA date](https://sec-api.dev/pdufa/tebipenem) | SPRO |  | completed, approved | "New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/d147628dex991.htm)) |
| June 18, 2026 | [Carbapenem PDUFA date](https://sec-api.dev/pdufa/carbapenem) | SPRO |  | scheduled | "FDA approval was received in advance of FDA-assigned Prescription Drug User Fee Act ("PDUFA") date of June 18, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1701108/000119312526277506/d51395d8k.htm)) |
| June 18, 2026 | [Abbv-rgx-314 dose 1 primary completion](https://sec-api.dev/pdufa/abbv-rgx-314) | ABBV | Diabetic Retinopathy (DR); Center-Involved Diabetic Macular Edema (CI-DME) | completed | "NCT04567550 (RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-18 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04567550)) |
| June 18, 2026 | [Bemnifosbuvir-ruzasvir (bem/rzr) primary completion](https://sec-api.dev/pdufa/bemnifosbuvir-ruzasvir-bem-rzr) | AVIR | HEPATITIS C VIRUS CHRONIC INFECTION | completed | "NCT06868264 (C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-18 (ACTUAL); Lead Sponsor Atea Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868264)) |
| June 19, 2026 | [Kiniksa Pharmaceuticals International, plc PDUFA date](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | scheduled | "Since then we have worked to qualify Samsung Biologics Co., Ltd. ("Samsung") as our replacement contract development and manufacturing organization ("CDMO") and, in April 2026, the FDA accepted the supplemental biologics license application related to such technology transfer and assigned a Prescription Drug User Fee Act target action date of June 19, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1730430/000110465926050359/knsa-20260331x10q.htm)) |
| June 19, 2026 | [WELIREG® (belzutifan) PDUFA date](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "Patients With Earlier-Stage RCC; Results From Phase 3 LITESPARK-022 Trial; FDA Set PDUFA Date of June 19, 2026 for WELIREG in combination with KEYTRUDA or KEYTRUDA QLEX" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm)) |
| June 19, 2026 | [Bimatoprost sr primary completion](https://sec-api.dev/pdufa/bimatoprost-sr) | ABBV | Open-Angle Glaucoma; Ocular Hypertension | completed | "NCT03891446 (Long-term Safety and Efficacy Extension Trial of Bimatoprost SR): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-19 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03891446)) |
| June 19, 2026 | [Encorafenib primary completion](https://sec-api.dev/pdufa/encorafenib) | PFE | Metastatic Colorectal Cancer | completed | "NCT05217446 (A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-19 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05217446)) |
| June 19, 2026 | [Golcadomide primary completion](https://sec-api.dev/pdufa/golcadomide) | BMY | Lymphoma, Follicular | completed | "NCT06425302 (A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-19 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06425302)) |
| June 20, 2026 | [Nda218995 complete response letter (CRL)](https://sec-api.dev/pdufa/nda218995) | QUIT |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218995_20260620_Redacted.pdf%22)) |
| June 2026 | [Iopofosine i 131 single dose primary completion](https://sec-api.dev/pdufa/iopofosine-i-131-single-dose) | CLRB | Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia | delayed | "NCT02952508 (Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-22 (ESTIMATED); Lead Sponsor Cellectar Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02952508)) |
| June 2026 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Neuromyelitis Optica Spectrum Disorder | delayed | "NCT05346354 (Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-06-22 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05346354)) |
| June 22, 2026 | [I004 primary completion](https://sec-api.dev/pdufa/i004) | AMPH | Pharmacokinetics; Pharmacodynamics; Insulin Aspart | completed | "NCT07560150 (Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-06-22 (ACTUAL); Lead Sponsor Amphastar Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07560150)) |
| June 23, 2026 | [QYLEKI (QRX003) FDA approval](https://sec-api.dev/pdufa/qrx003) | QNRX |  | completed, approved | "On June 23, 2026, we received conditional FDA approval of QYLEKI as the proposed brand name for QRX003 for Netherton Syndrome." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1671502/000110465926097064/qnrx-20260630x10q.htm)) |
| June 23, 2026 | [Erbitux® (cetuximab) trial start](https://sec-api.dev/pdufa/cetuximab) | VSTM |  | completed | "Announce first patient dosed in the TARGET-D 202 and TARGET-D 203 clinical trials in mid-2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926076809/tm2618546d1_8k.htm)) |
| June 23, 2026 | [Surabgene trial start](https://sec-api.dev/pdufa/surabgene) | RGNX |  | completed | "REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526286825/rgnx-ex99_1.htm)) |
| June 23, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Hepatocellular Carcinoma | completed | "NCT04740307 (Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-23." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04740307?tab=results)) |
| June 23, 2026 | [Envudeucitinib primary completion](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | SLE | completed | "NCT05966480 (Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-23 (ACTUAL); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05966480)) |
| June 23, 2026 | [Joenja® (leniolisib) primary completion](https://sec-api.dev/pdufa/leniolisib) | PHAR | Primary Immunodeficiency Disorders (PIDs) | completed | "NCT06549114 (Leniolisib for Immune Dysregulation in PIDs): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-23 (ACTUAL); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06549114)) |
| June 23, 2026 | [Rsvpref3 oa investigational vaccine topline data readout](https://sec-api.dev/pdufa/rsvpref3-oa-investigational-vaccine) | GSK | Respiratory Syncytial Virus Infections | completed | "NCT06614725 (A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-23." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06614725?tab=results)) |
| June 23, 2026 | [VHB937 primary completion](https://sec-api.dev/pdufa/vhb937) | NVS | Amyotrophic Lateral Sclerosis (ALS) | completed | "NCT06643481 (A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-23 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06643481)) |
| June 24, 2026 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20260624, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| June 24, 2026 | [TRYNGOLZA (olezarsen) FDA approval](https://sec-api.dev/pdufa/olezarsen) | IONS | sHTG | completed, approved | "On June 24, 2026, Ionis announced that the U.S. FDA has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with sHTG." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/874015/000114036126026232/ef20076807_8k.htm)) |
| June 24, 2026 | [Tremfya (guselkumab) topline data readout](https://sec-api.dev/pdufa/guselkumab) | JNJ | Plaque Psoriasis; Scalp Psoriasis | completed | "NCT05272150 (Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-06-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05272150?tab=results)) |
| June 24, 2026 | [Eloralintide topline data readout](https://sec-api.dev/pdufa/eloralintide) | LLY | Obesity; Overweight | completed | "NCT06230523 (A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06230523?tab=results)) |
| June 24, 2026 | [IMCIVREE® (setmelanotide) primary completion](https://sec-api.dev/pdufa/setmelanotide) | RYTM | Obesity Associated With Defects in Leptin-melanocortin Pathway | completed | "NCT06596135 (Open-Label Extension Study of Setmelanotide): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-24 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06596135)) |
| June 24, 2026 | [ALXN2420 primary completion](https://sec-api.dev/pdufa/alxn2420) | AZN | Acromegaly | withdrawn | "NCT07037420 (ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-24 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07037420)) |
| June 24, 2026 | [IBRANCE® (palbociclib) label expansion decision](https://sec-api.dev/pdufa/palbociclib) | PFE |  | completed, approved | "NDA212436 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260624, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22)) |
| June 24, 2026 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-187 (Efficacy): submission_status AP, submission_status_date 20260624, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| June 25, 2026 | [Repatha (evolocumab) topline data readout](https://sec-api.dev/pdufa/evolocumab) | AMGN | Coronary Heart Disease (CHD) | completed | "NCT03872401 (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-06-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03872401?tab=results)) |
| June 25, 2026 | [Standard lymphodepletion regimen primary completion](https://sec-api.dev/pdufa/standard-lymphodepletion-regimen) | KYTX | Stiff-Person Syndrome; SPS | completed | "NCT06588491 (KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-25 (ACTUAL); Lead Sponsor Kyverna Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588491)) |
| June 25, 2026 | [JNJ-89495120 primary completion](https://sec-api.dev/pdufa/jnj-89495120) | JNJ | Depressive Disorder, Major | completed | "NCT06785012 (A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-25 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06785012)) |
| June 25, 2026 | [SION-719 primary completion](https://sec-api.dev/pdufa/sion-719) | SION | Cystic Fibrosis (CF) | completed | "NCT07108153 (Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-25 (ACTUAL); Lead Sponsor Sionna Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07108153)) |
| June 26, 2026 | [Opdivo® (nivolumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/nivolumab) | REPL |  | completed | "On June 26, 2026 we announced the FDA accepted the BLA resubmission as a Class 1 resubmission with an action date of August 2, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm)) |
| June 26, 2026 | [Lumvoa™ (veligrotug) FDA approval](https://sec-api.dev/pdufa/veligrotug) | VRDN | thyroid eye disease | completed, approved | "On June 26, 2026, Viridian Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease ("TED") regardless of activity or duration." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211d8k.htm)) |
| June 26, 2026 | [Deramiocel FDA advisory committee meeting](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | scheduled | "On June 26, 2026, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing that the Cellular, Tissue, and Gene Therapies Advisory Committee of the U.S. Food and Drug Administration ("FDA") is planning to convene an Advisory Committee meeting to discuss the Company's Biologics License Application ("BLA") seeking approval of Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy ("DMD")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/capr-20260626x8k.htm)) |
| June 26, 2026 | [Lumvoa™ (veligrotug) PDUFA date](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | completed, approved | "- Lumvoa (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S. -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744dex991.htm)) |
| June 26, 2026 | [AZD9833 primary completion](https://sec-api.dev/pdufa/azd9833) | AZN | ER-Positive HER2-Negative Breast Cancer | completed | "NCT04711252 (A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-26 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04711252)) |
| June 26, 2026 | [ASTRAZENECA PLC topline data readout](https://sec-api.dev/companies/azn/catalysts) | AZN | Chronic Kidney Disease | completed | "NCT06350123 (Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-09 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-06-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06350123?tab=results)) |
| June 26, 2026 | [Cagrisema (cagrilintide b and semaglutide i) primary completion](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) | NVO | Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy | completed | "NCT06797869 (A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-26 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06797869)) |
| June 26, 2026 | [Participants will receive one dose of vaccine (0.5 ml) of sinovac qiv primary completion](https://sec-api.dev/pdufa/participants-will-receive-one-dose-of-vaccine) | SVA | Influenza | completed | "NCT07211152 (Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-26 (ACTUAL); Lead Sponsor Sinovac Biotech Co., Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07211152)) |
| June 26, 2026 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 SUPPL-45 (Efficacy): submission_status AP, submission_status_date 20260626, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| June 26, 2026 | [Lumvoa (veligrotug-vvze) FDA approval](https://sec-api.dev/pdufa/veligrotug-vvze) | VRDN | To treat thyroid eye disease | completed, approved | "Lumvoa \| veligrotug-vvze \| 6/26/2026 \| To treat thyroid eye disease" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| June 28, 2026 | [Stannous fluoride toothpaste primary completion](https://sec-api.dev/pdufa/stannous-fluoride-toothpaste) | CL | Plaque; Gingivitis | completed | "NCT07458464 (Study to Investigate Toothpaste on Antibacterial Effects in the Different Regions of the Mouth): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-28 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07458464)) |
| June 29, 2026 | [Nomlabofusp NDA/BLA submission](https://sec-api.dev/pdufa/nomlabofusp) | LRMR | broad population of patients | completed | "On June 29, 2026, Larimar Therapeutics, Inc. (the "Company") issued a press release announcing (i) that it has submitted the first module of the Company's rolling Biologics License Application submission to the Food and Drug Administration for accelerated approval of nomlabofusp and (ii) positive data from the Company's ongoing long-term open label study evaluating daily subcutaneous injections of nomlabofusp in adolescent and adult patients with Friedreich's ataxia." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1374690/000119312526286780/lrmr-20260629.htm)) |
| June 29, 2026 | [Vusolimogene oderparepvec NDA/BLA acceptance](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL | advanced melanoma | completed | "The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926078511/tm2619129d1_ex99-1.htm)) |
| June 29, 2026 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX |  | completed, positive | "On June 29, 2026, we announced positive topline results from Part 2 of our Phase 3 ABTECT 44-week maintenance trial evaluating obefazimod, our potential first-in-class oral miR-124 enhancer, in moderate to severely active UC." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526294491/d111359d424b5.htm)) |
| June 29, 2026 | [Surabgene lomparvovec trial start](https://sec-api.dev/pdufa/surabgene-lomparvovec) | RGNX |  | completed | "ROCKVILLE, Md., June 29, 2026 - REGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526286825/rgnx-ex99_1.htm)) |
| June 29, 2026 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315226031103/ex99-1.htm)) |
| June 29, 2026 | [ZORYVE (roflumilast) PDUFA date](https://sec-api.dev/pdufa/roflumilast) | ARQT | plaque psoriasis in children down | completed, approved | "•sNDA accepted for ZORYVE cream 0.3% for the treatment of plaque psoriasis down to 2 years of age with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000017/pressreleaseex991q42025.htm)) |
| June 29, 2026 | [Replimune Group, Inc. earnings report](https://sec-api.dev/companies/repl/catalysts) | REPL |  | completed | "(Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926078511/tm2619129d1_ex99-1.htm)) |
| June 29, 2026 | [Oxylanthanum PDUFA date](https://sec-api.dev/pdufa/oxylanthanum) | UNCY |  | scheduled | "Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/ea029027701ex99-1.htm)) |
| June 29, 2026 | [Dn-tnf topline data readout](https://sec-api.dev/pdufa/dn-tnf) | INMB | Alzheimer Disease; Dementia; Brain Diseases | completed | "NCT05318976 (A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-12 (ACTUAL); Lead Sponsor Inmune Bio, Inc.; Results First Posted 2026-06-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05318976?tab=results)) |
| June 29, 2026 | [Qulipta (atogepant) primary completion](https://sec-api.dev/pdufa/atogepant) | ABBV | Menstrual Migraine (MM) | completed | "NCT06806293 (Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-29 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06806293)) |
| June 29, 2026 | [Tetravalent dengue vaccine (tdv) primary completion](https://sec-api.dev/pdufa/tetravalent-dengue-vaccine-tdv) | TAK | Dengue Fever | completed | "NCT07047521 (A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-29 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07047521)) |
| June 29, 2026 | [Oral semaglutide primary completion](https://sec-api.dev/pdufa/oral-semaglutide) | NVO | Type 2 Diabetes | completed | "NCT07271251 (A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-29 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07271251)) |
| June 29, 2026 | [Nda218607 complete response letter (CRL)](https://sec-api.dev/pdufa/nda218607) | UNCY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218607_20260629.pdf%22)) |
| June 29, 2026 | [ZORYVE (roflumilast) label expansion decision](https://sec-api.dev/pdufa/roflumilast) | ARQT | children with plaque psoriasis down | completed, approved | "NDA215985 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20260629, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22)) |
| June 30, 2026 | [Inluriyo™ (imlunestrant) complete response letter (CRL)](https://sec-api.dev/pdufa/imlunestrant) | LONA |  | completed, complete response letter | "The Series A Common Warrants have an exercise price of $6.35 per share and are exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Company publicly announces the enrollment of the 500th subject or the last subject, whichever is earlier, in the ELAINE-3 trial; and (c) the date on which the FDA approves or issues a complete response letter to Eli Lilly & Co.'s marketing application, including a supplement to a new drug application, for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 ( the "Series A Common Warrant Initial Exercise Date")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1620463/000119312526352243/lona-20260630.htm)) |
| June 30, 2026 | [Lumvoa™ (veligrotug) topline data readout](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | scheduled | "FDA, with PDUFA target date of June 30, 2026 Topline results reported December 2024 Met all primary & secondary endpoints Topline results reported September 2024 Met all primary & secondary endpoints Veligrotug met the primary and all secondary endpoints with statistical significance in two phase 3 trials, THRIVE and THRIVE-2" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955dex992.htm)) |
| June 30, 2026 | [LENZ Therapeutics, Inc. FDA approval](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed, approved | "Through June 30, 2026, the Company has devoted substantially all of its efforts to product development, pre-commercial and commercial activities following the FDA approval of VIZZ in July 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000052/lenz-20260630.htm)) |
| June 30, 2026 | [Unicycive Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed, complete response letter | "On June 30, 2026, we announced that we received a CRL from the FDA regarding the resubmitted NDA for OLC." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm)) |
| June 30, 2026 | [KAMADA LTD FDA approval](https://sec-api.dev/companies/kmda/catalysts) | KMDA |  | completed, approved | "Announced FDA approval of the Company's new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567529/000121390026088030/ea029970701ex99-1.htm)) |
| June 30, 2026 | [Lumvoa™ (veligrotug) PDUFA date](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | completed, approved | "- PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease (TED); organization is launch-ready -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/d149508dex991.htm)) |
| June 30, 2026 | [Spikevax (spikevax) FDA approval](https://sec-api.dev/pdufa/spikevax) | MRNA |  | completed, approved | "As of June 30, 2026, we have four approved products, our COVID vaccines, Spikevax and mNEXSPIKE, our RSV vaccine, mRESVIA, and our flu plus COVID combination vaccine, mCOMBRIAX. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease caused by RSV." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm)) |
| June 30, 2026 | [LeonaBio, Inc. topline data readout](https://sec-api.dev/companies/lona/catalysts) | LONA |  | scheduled | "The PIPE Series B Common Warrants will have an exercise price of $7.62 per share payable on a cashless net exercise basis, subject to adjustments as provided therein, and will be exercisable, subject to the restrictions discussed below, after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the ELAINE-3 Trial (the later of (1) and (2), the "Series B Common Warrant Initial Exercise Date")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1620463/000119312525323692/atha-20251218.htm)) |
| June 30, 2026 | [BRUKINSA® (zanubrutinib) topline data readout](https://sec-api.dev/pdufa/zanubrutinib) | ONC | previously untreated mantle cell lymphoma | completed, positive | "On June 30, 2026, we announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306) evaluating foundational Bruton's tyrosine kinase ("BTK") inhibitor BRUKINSA® plus rituximab versus bendamustine plus rituximab in adult patients with previously untreated mantle cell lymphoma ("MCL")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1651308/000162828026052878/bgne-20260630.htm)) |
| June 30, 2026 | [PTC612 trial start](https://sec-api.dev/pdufa/ptc612) | PTCT |  | completed | "During the quarter ended June 30, 2026, the Company initiated a Phase 1 study of PTC612, its oral NLRP3 inhibitor, and completed several of the single and multiple ascending dose treatment cohorts." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000017/tmb-20260630x10q.htm)) |
| June 30, 2026 | [YUVIWEL® (navepegritide) FDA approval](https://sec-api.dev/pdufa/navepegritide) | ASND |  | completed, approved | "Further, the six months ended June 30, 2026 included a reversal (income) of prior period write-downs related to pre-launch inventories for Growth Disorders of €10.9 million due to the U.S. FDA approval of YUVIWEL." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000161204226000016/asnd-20260630.htm)) |
| June 30, 2026 | [TRYNGOLZA (olezarsen) PDUFA date](https://sec-api.dev/pdufa/olezarsen) | IONS | severe hypertriglyceridemia, or sHTG, with an action date of June 30, 2026 | completed, approved | "Olezarsen on track to launch this year as a transformational medicine for severe hypertriglyceridemia (sHTG), assuming approval o sNDA accepted by the FDA for Priority Review for the treatment of sHTG with a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026 o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/ef20071749_ex99-1.htm)) |
| June 30, 2026 | [Viridian Therapeutics, Inc.\DE PDUFA date](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | scheduled | "PDUFA target: June 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977dex992.htm)) |
| June 30, 2026 | [Peptibody topline data readout](https://sec-api.dev/pdufa/peptibody) | NBP |  | completed, positive | "During the six months ended June 30, 2026, positive Phase 2a topline results were reported and preparations continued for initiation of a Phase 2b study in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1778016/000119312526357819/nbp-ex99_3.htm)) |
| June 30, 2026 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of June 30, 2026, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated an investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in locally advanced head and neck squamous cell carcinoma in 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000119312526352128/cue-20260630.htm)) |
| June 30, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Urinary Bladder Cancer, Muscle-invasive | completed | "NCT03924895 (Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-06 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03924895?tab=results)) |
| June 2026 | [Lomecel-b medicinal signaling cells primary completion](https://sec-api.dev/pdufa/lomecel-b-medicinal-signaling-cells) | LGVN | Hypoplastic Left Heart Syndrome | delayed | "NCT04925024 (Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-30 (ESTIMATED); Lead Sponsor Longeveron Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04925024)) |
| June 2026 | [Revtorpyk (gedatolisib) primary completion](https://sec-api.dev/pdufa/gedatolisib) | CELC | Breast Cancer | delayed | "NCT05501886 (Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ESTIMATED); Lead Sponsor Celcuity Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05501886)) |
| June 2026 | [Obexelimab primary completion](https://sec-api.dev/pdufa/obexelimab) | ZBIO | Warm Autoimmune Hemolytic Anemia | delayed | "NCT05786573 (A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05786573)) |
| June 30, 2026 | [TNX-103 primary completion](https://sec-api.dev/pdufa/tnx-103) | TENX | Pulmonary Hypertension | completed | "NCT05983250 (LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ACTUAL); Lead Sponsor Tenax Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05983250)) |
| June 30, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06010004 (A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06010004?tab=results)) |
| June 30, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma (HCC) | completed | "NCT06040099 (A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-30 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06040099)) |
| June 30, 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Lung Cancer, Non-Small Cell | completed | "NCT06472076 (A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06472076)) |
| June 2026 | [Aroxybutynin and atomoxetine primary completion](https://sec-api.dev/pdufa/aroxybutynin-and-atomoxetine) | APMD | OSA | delayed | "NCT06566820 (Continuation Protocol for Obstructive Sleep Apnea (OSA)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-06-30 (ESTIMATED); Lead Sponsor Apnimed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06566820)) |
| June 2026 | [89zr-tlx250 pet/ct primary completion](https://sec-api.dev/pdufa/89zr-tlx250-pet-ct) | TLX | Clear Cell Renal Cell Carcinoma | delayed | "NCT06750419 (89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750419)) |

Other months: https://sec-api.dev/fda-calendar/2026-05 , https://sec-api.dev/fda-calendar/2026-07. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates June 2026: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2026-06

```bibtex
@misc{secapidev_fda_calendar_2026_06_20261116,
  title        = {PDUFA dates June 2026: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2026-06}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2026_06_20261116","title":"PDUFA dates June 2026: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2026-06","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
